COMMENTARY

Gynecologic Cancer Studies to Look For at ASCO 2018

Maurie Markman, MD

Disclosures

May 24, 2018

Hello. I'm Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss several very interesting abstracts that are going to be presented at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO) in gynecologic oncology, specifically the oral abstracts presented on Tuesday morning.

There are studies that analyze phase 1 clinical trials and include some interesting data. There is a very interesting section on surgery for gynecologic malignancies and one abstract in particular: a randomized phase 3 trial conducted by the Gynecologic Oncology Group. [This study] assessed the value of secondary surgical cytoreduction in patients with recurrent ovarian cancer and demonstrated no impact from surgery on survival.[1] That's going to be an interesting presentation.

There will be a discussions about robotics—a topic of great interest to clinicians—as well as neoadjuvant chemotherapy. There is also a very interesting abstract that looked at the potential benefits of adding bevacizumab to second-line chemotherapy in patients who had already received bevacizumab in the upfront, first-line setting.[2] This abstract demonstrated an improvement in progression-free survival with the addition of bevacizumab, despite the fact that the patients had had bevacizumab in the upfront setting.

This is going to be a very interesting session. For those of you interested in gynecologic malignancies, I would certainly encourage you to attend that session, or certainly, at a minimum, look at the abstracts that are actually available online.

The ASCO meeting is always very exciting. There are so many things going on in the gynecologic oncology sessions, which include not only the oral session I mentioned, but also poster sessions that should be very interesting, very provocative, and very important from the perspective of new developments, as well as the results of clinical trials. Thank you for your attention.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....